Lumos Diagnostics Holdings (ASX:LDX) completed the enrollment of 250 patients in the Biomedical Advanced Research and Development Authority (BARDA)-funded pediatric clinical study of the FebriDx rapid point-of-care test for acute respiratory infections, according to a Thursday Australian bourse filling.
This triggered a $670,000 milestone payment under Lumos' agreement with BARDA, bringing the total milestone payments received to date to $2.6 million, the filing said.
The study is evaluating the use of the FebriDx device in children between the ages of two to 12 years to differentiate bacterial from non-bacterial acute respiratory infections, per the filing. It is expected to run for around 12 months.
Lumos Diagnostics Holdings' shares tumbled 4% in recent Thursday trade.